Home Page

Over 100 million people worldwide suffer
from Central Nervous System diseases.

We think our research can
make a difference.


Our Passion

Gene Solutions conducts therapeutic drug discovery research for Central Nervous System (CNS) diseases, utilizing its proprietary mitochondrial genomic targets. The company’s primary CNS indications of interest are Alzheimer’s, Parkinson’s and Schizophrenia. NCE discovery research is conducted at the company’s two locations in the USA and UK, while company-developed assays are executed with leading academic collaboration partners. Adding to a comprehensive and unparalleled approach, the company’s unique biomarkers have utility in clinical patient screening and data generation, as well as blood-based companion diagnostics. We partner with pharmaceutical and biotechnology companies to bring novel and vital cures to large segments of our population. We invite you to build upon our cutting-edge research to advance the treatment of devastating diseases affecting large segments of our global population.

Our People

Gene Solutions management is deeply experienced in Central Nervous System (CNS) science and research and offers partners a perfect blend of scientific and business expertise.

Co-Founder, President and Director
CFO and Director
Business Development and Director
Director and head of Chemistry Lead Discovery


Inside UVA OnLine: March 26- April 8, 2004,
Vol 34, Issue 6: Davis Parker’s Magnum Opus

Parker WD Jr, Parks JK, Swerdlow RH.
Complex I deficiency in Parkinson's disease frontal cortex.
Brain Res. 2008 Jan 16;1189:215-8. Epub 2007 Nov 1. PMID: 18061150 [PubMed - indexed for MEDLINE]

McAllister J, Ghosh S, Berry D, Park M, Sadeghi S, Wang KX, Parker WD, Swerdlow RH.
Effects of memantine on mitochondrial function.
Biochem Pharmacol. 2008 Feb 15;75(4):956-64. Epub 2007 Oct 23. PMID: 18053965 [PubMed - indexed for MEDLINE]